椰子水诱导轻中度溃疡性结肠炎临床缓解:双盲安慰剂对照试验
这项单中心双盲安慰剂对照试验将95例轻中度活动性溃疡性结肠炎患者按1:1随机分为椰子水联合标准药物治疗组与安慰剂联合标准药物治疗组,椰子水400mL用8周。椰子水组临床缓解率53.1% vs 安慰剂组28.3%(OR 2.9,95%CI 1.2-6.7,P=.02),临床应答率57.1% vs 28.3%(OR 3.4,95%CI 1.4-7.9,P=.01),粪钙卫蛋白<150μg/g比例30.6% vs 6.5%(OR 6.3,95%CI 1.7-23.6,P=.003)均显著更高,不良事件相当,无高钾血症发生。
要点
- 椰子水联合标准药物治疗8周,临床缓解率53.1% vs 安慰剂28.3%(OR 2.9,95%CI 1.2-6.7,P=.02)。
- 椰子水组临床应答率57.1% vs 安慰剂28.3%(OR 3.4,95%CI 1.4-7.9,P=.01)。
- 粪钙卫蛋白<150μg/g比例椰子水组30.6% vs 安慰剂组6.5%(OR 6.3,95%CI 1.7-23.6,P=.003),不良事件相当。
核心结论
- 椰子水在诱导轻中度溃疡性结肠炎临床缓解方面比安慰剂更有效。
研究设计与样本
- 单中心、双盲、安慰剂对照试验,将轻中度(SCCAI 3-9)内镜下活动性UC(UCEIS>1)患者按1:1随机分为椰子水+标准药物治疗组与安慰剂+标准药物治疗组。
- 椰子水400mL给药8周。
- 筛查121例,95例纳入改良意向治疗分析(椰子水组n=49,安慰剂组n=46)。
- 纳入患者平均年龄37.2±11.2岁,男性54.1%,病程48个月(IQR 24-90个月),全结肠炎26.1%,SCCAI 5(IQR 4-6),UCEIS 4(IQR 3-5)。
- 主要结局为临床缓解(SCCAI≤2),次要结局为临床应答(SCCAI下降≥3)和8周不良事件;基线和8周分析微生物组。
主要发现
- 临床应答率椰子水组57.1% vs 安慰剂组28.3%(OR 3.4,95%CI 1.4-7.9,P=.01)。
- 临床缓解率椰子水组53.1% vs 安慰剂组28.3%(OR 2.9,95%CI 1.2-6.7,P=.02)。
- 粪钙卫蛋白<150μg/g的患者比例椰子水组30.6% vs 安慰剂组6.5%(OR 6.3,95%CI 1.7-23.6,P=.003)。
- 与SCCAI、UCEIS或FCP呈显著负相关或趋势负相关的细菌类群相对丰度在椰子水组8周时增加,该效应独立于疾病活动和膳食纤维。
- 不良事件相当,无患者发生高钾血症。
关键数值与推荐
- 临床缓解定义为SCCAI≤2。
- 临床应答定义为SCCAI下降≥3。
- 入组标准为轻中度(SCCAI 3-9)且内镜下活动性(UCEIS>1)的溃疡性结肠炎。
- 椰子水剂量为400mL,给药8周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Coconut water (CW) is anti-inflammatory, can manipulate the gut microbiome, and is a rich source of potassium. Gut microbiome modulation improves outcomes in ulcerative colitis (UC), and potassium possesses in vitro anti-inflammatory property. We evaluated the effect of CW as an adjunct therapy for patients with mild-moderate UC. METHODS: This single-center, double-blind, placebo-controlled trial randomized patients with mild to moderate (Simple Clinical Colitis Activity Index [SCCAI]: 3-9) endoscopically active UC (Ulcerative Colitis Endoscopic Index of Severity [UCEIS] >1) in 1:1 ratio to CW + standard medical therapy (SMT) vs placebo + SMT. Four hundred mL of CW was administered for 8 weeks. Primary outcome measure was clinical remission (SCCAI ≤2), and secondary outcome measures were clinical response (SCCAI decline ≥3) and adverse events at 8 weeks. Microbiome was analyzed at baseline and 8 weeks. RESULTS: Of 121 patients screened, 95 were included for modified intention to treat analysis (CW, n = 49; placebo, n = 46) (mean age, 37.2 ± 11.2 years; males, 54.1%; disease duration, 48 months [interquartile range (IQR), 24-90 months]; pancolitis, 26.1%; SCCAI, 5 [IQR, 4-6]; UCEIS, 4 [IQR, 3-5]). Clinical response (57.1% vs 28.3%; odds ratio [OR], 3.4; 95% confidence interval [CI], 1.4-7.9; P = .01), remission (53.1% vs 28.3%; OR, 2.9; 95% CI, 1.2-6.7; P = .02), and proportion of patients with fecal calprotectin (FCP) <150 μg/g (30.6% vs 6.5%; OR, 6.3; 95% CI, 1.7-23.6; P = .003) were significantly higher in CW. The relative abundance of bacterial taxa that had a significant or trend towards negative correlation with SCCAI, UCEIS, or FCP increased at 8 weeks in CW, and this effect was independent of disease activity and dietary fiber. Adverse events were comparable, and no patient developed hyperkalemia. CONCLUSIONS: CW was more effective than placebo for induction of clinical remission in patients with mild to moderate UC. The trial was prospectively registered on Clinical Trials Registry of India (ctri.nic.in, Number: CTRI/2019/03/01827).
引用
- Kedia S, Virmani S, Bajaj A, et al. Coconut Water Induces Clinical Remission in Mild to Moderate Ulcerative Colitis: Double-blind Placebo-controlled Trial. Clin Gastroenterol Hepatol. 2024. PMID: 38278200. doi:10.1016/j.cgh.2024.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。